Memic Adnan, Navaei Ali, Mirani Bahram, Cordova Julio Alvin Vacacela, Aldhahri Musab, Dolatshahi-Pirouz Alireza, Akbari Mohsen, Nikkhah Mehdi
Center of Nanotechnology, King Abdulaziz University, Jeddah, Saudi Arabia.
Biomaterials Research Innovation Center, Harvard Medical School, Brigham and Women's Hospital, Cambridge, MA, USA.
Biotechnol Lett. 2017 Sep;39(9):1279-1290. doi: 10.1007/s10529-017-2360-z. Epub 2017 May 26.
There is a great need for the development of biomimetic human tissue models that allow elucidation of the pathophysiological conditions involved in disease initiation and progression. Conventional two-dimensional (2D) in vitro assays and animal models have been unable to fully recapitulate the critical characteristics of human physiology. Alternatively, three-dimensional (3D) tissue models are often developed in a low-throughput manner and lack crucial native-like architecture. The recent emergence of bioprinting technologies has enabled creating 3D tissue models that address the critical challenges of conventional in vitro assays through the development of custom bioinks and patient derived cells coupled with well-defined arrangements of biomaterials. Here, we provide an overview on the technological aspects of 3D bioprinting technique and discuss how the development of bioprinted tissue models have propelled our understanding of diseases' characteristics (i.e. initiation and progression). The future perspectives on the use of bioprinted 3D tissue models for drug discovery application are also highlighted.
迫切需要开发仿生人体组织模型,以阐明疾病发生和发展过程中涉及的病理生理状况。传统的二维(2D)体外检测方法和动物模型无法完全重现人体生理学的关键特征。另外,三维(3D)组织模型的开发通常采用低通量方式,并且缺乏关键的类天然结构。生物打印技术的最新出现使得能够创建3D组织模型,通过开发定制生物墨水和患者来源的细胞以及生物材料的明确排列来应对传统体外检测的关键挑战。在这里,我们概述了3D生物打印技术的技术方面,并讨论了生物打印组织模型的发展如何推动我们对疾病特征(即发生和发展)的理解。还强调了使用生物打印3D组织模型进行药物发现应用的未来前景。